公开(公告)号：US10653764B2

公开(公告)日：2020-05-19

申请号：US15542802

申请日：2016-01-05

Applicant: Pfizer Inc.

Inventor： David Cooper ,  Kathrin Ute Jansen ,  Michael William Pride

IPC: A61K39/02 ,  A61K39/116 ,  A61K39/00 ,  A61K39/09 ,  A61K39/385

Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

公开(公告)号：US09492559B2

公开(公告)日：2016-11-15

申请号：US14597488

申请日：2015-01-15

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/09 ,  A61K39/385 ,  A61K47/48

CPC classification number: A61K47/4833 ,  A61K39/092 ,  A61K47/646 ,  A61K2039/6037 ,  A61K2039/70 ,  Y02A50/466

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

Abstract translation: 本发明涉及包含结合性肺炎链球菌荚膜糖抗原（糖缀合物）的新的免疫原性组合物及其应用。 本发明的免疫原性组合物通常将包含至少一种来自PREVNAR，SYNFLORIX和/或PREVNAR 13中没有发现的肺炎链球菌血清型的糖缀合物。 本发明还涉及使用所述新型免疫原性组合物对人受试者，特别是婴儿和老年人免疫肺炎球菌感染。